Division within @dukemedicine and multidisciplinary program within @DukeCancer focused in blood cancer, stem cell transplantation, and cell & gene therapy.
Durham, NC
Joined May 2019
- Tweets1.1K
- Following178
- Followers625
- Likes1.8K
"Building Bridges Beyond Cancer: How Oncology Infrastructure Can Help Scale Cell and Gene Therapy Across Health Systems."
The Duke Center for Cell and Gene Therapy will be launching on July 6th, 2026! @DukeCancer
Read more:
astct.org/Nucleus/Article/bu…
Congratulations to Dr. @LouisDiehl2, an incredible clinician and medical educator who is retiring after a storied career at @WRNMMC_DHA and @DukeCancer. Thank you for your service!
Finishing strong with Monday presentations by our @DukeCancer faculty at #ASH25! Featuring @AndreaSitlinger @ChenyuLinMD @tomleblancMD
Come interact with our faculty and trainees on the Sunday evening poster session #ASH25!
Come check out our @DukeCancer faculty presentations at #ASH25 on Saturday, December 6th!
A strong start to #ASH25 with @LindsayReinMD and #HarryErba kicking off the Friday Satellite Symposia!
Duke Hematologic Malignancies & Cellular Therapy retweeted
DCI is participating in a national clinical trial that could reshape the future of CAR T-cell therapy for patients with aggressive lymphoma.
duke.is/w/8xat
@DukeMedSchool | @DukeHealth | @DukeHMCT
A warm welcome to our newest faculty member, Dr. Alexander Dew! Dr. Dew joins @DukeCancer from Walter Reed, where he had served as director of autologous stem cell transplantation. He sees patients with plasma cell disorders, including #myeloma.
dukehealth.org/find-doctors-…
Duke Hematologic Malignancies & Cellular Therapy retweeted
CAR #HEMATOTOX is associated with brexu-cel response, survival, and neutrophil recovery in #ALLsm. Great collaboration with @MSKCancerCenter Yannis Valtis & Jae Park, and #ROCCA consortium @StanfordCancer @LoriMuffly @UChicagoLeuk @RoloffGreg. @DukeCancer
ashpublications.org/bloodadv…
Take a look at this @FrontiersIn mini-review of reduced & weekly dosing of selinexor in #myeloma, with senior author @Cristin53875581
frontiersin.org/journals/onc…
Duke Hematologic Malignancies & Cellular Therapy retweeted
📝 Updated data from the KOMET-007 trial, presented by Harry Erba at #EHA2025, show that ziftomenib with intensive induction therapy was well tolerated in patients with newly diagnosed NPM1m or KMT2Ar AML.
More news: aml-hub.com/
#AMLsm #leusm #MedNews #MedEd
Congratulations to @DukeCancer faculty Dr. Yubin Kang for his new @CancerResearch CLIP award studying how targeting SK2 can enhance CAR T cell therapy efficacy in multiple myeloma #mmsm
cancerresearch.org/wp-conten…
Duke Hematologic Malignancies & Cellular Therapy retweeted
Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses. #MDS | @tomleblancMD @DukeCancer
hubs.li/Q03wgGSn0
Take a look at this review of advancements in countermeasures against #radiation injuries from the Centers for Medical Countermeasures against Radiation Consortium (CMCRC), with former @DukeHMCT division chief #NelsonChao as senior author.
pubmed.ncbi.nlm.nih.gov/4057…
This @CIBMTR retrospective study showed that solid organ transplant outcomes following stem cell transplantation varied depending on the organ transplanted. Liver transplants had worse outcomes compared to kidney transplants. Featuring @horwi001 as a co-author.
pubmed.ncbi.nlm.nih.gov/4054…
The BELLINI trial showed that Vd-ven had worse overall survival than Vd-placebo in patients with relapsed multiple #myeloma, indicating that #venetoclax should be avoided in the general R/R myeloma population. Featuring @Cristin53875581 as an author.
thelancet.com/journals/lanha…
Congratulations to our faculty @tomleblancMD for this important work!
Multisite Randomized Trial of Inpatient #Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation.
ascopubs.org/doi/10.1200/JCO…
@ASCO @JCO_ASCO @JCOOP_ASCO
#PallOnc #PalliativeCare #SuppOnc
@Areejmd @tomleblancMD @MGHCancerCenter
Duke Hematologic Malignancies & Cellular Therapy retweeted
Explore the complexities of chronic #GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies in this article from Targeted Oncology: hubs.li/Q03tll7V0 | @DukeHMCT @dukemedicine @DukeHealth
Preclinical and early phase clinical data suggests a role for dual #FLT3 and MDM2 inhibition using #quizartinib and #milademetan in FLT3-ITD mutated #AML, featuring faculty #HarryErba as a co-author. @CCR_AACR #leusm
aacrjournals.org/clincancerr…
This cross-sectional study in @JCOOP_ASCO showed that cancer survivors were more likely to get alcohol screening, with similar rates of alcohol intervention when needed, highlighting opportunities for improvement. Featuring Vice-Chief @AndreaSitlinger.
ascopubs.org/doi/10.1200/OP-…
